Prospective Evaluation of the Cardiovascular Effects of BRAF and MEK Inhibitors in Patients With Melanoma
Authors' conclusion
BRAF inhibitor- and MEK inhibitor-associated hypertension and CTRCD are common.
Study context
- Population
- Patients with melanoma treated with BRAF and MEK inhibitors, regional cancer network, March 2021 to March 2023
- Participants
- 61 patients
- Outcome
- Incidence and risk factors for BRAF/MEK inhibitor-associated hypertension and CTRCD (International Cardio-Oncology Society definitions)
- Follow-up
- Baseline and 4, 12 and 24 weeks
Methodological detailslongitudinal, regional cancer network
- Longitudinal
- Regional cancer network
Main finding
As reported in the abstract
- Hypertension
- 28 (45.9%)
- Cancer therapy-related cardiac dysfunction (CTRCD)
- 45.9%
- Mild CTRCD
- 24 (85.7%)
- Moderate CTRCD
- 3 (10.7%)
- Severe CTRCD
- 1 (3.6%)
- Moderate or severe CTRCD in low baseline risk
- 0
Observational data: associations, not effects.
Further findings
Baseline NT-proBNP, CTRCD vs no CTRCD · median baseline
P = 0.047
Hypertension, CMR myocardial or perfusion characteristics and incident CTRCD
- No robust associations
Original publication
Prospective Evaluation of the Cardiovascular Effects of BRAF and MEK Inhibitors in Patients With Melanoma. JACC CardioOncol. Published 10 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →